In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Rallybio (RLYB – Research Report), with a price target of $37.00. The company’s shares opened today at $8.52.
Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Madrigal Pharmaceuticals, and Clearside Biomedical. According to TipRanks, Wolleben has an average return of -12.3% and a 31.08% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rallybio with a $37.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $21.00 and a one-year low of $5.90. Currently, Rallybio has an average volume of 57.08K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Read More on RLYB:
